应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02552 华领医药-B
未开盘 05-03 16:09:00
1.590
-0.020
-1.24%
最高
1.640
最低
1.550
成交量
29.40万
今开
1.600
昨收
1.610
日振幅
5.59%
总市值
16.78亿
流通市值
16.78亿
总股本
10.56亿
成交额
46.74万
换手率
0.03%
流通股本
10.56亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股异动 | 华领医药-B(02552)涨超5% 第二代GKA在美启动一期临床试验并完成首例受试者入组
智通财经 · 04-26
港股异动 | 华领医药-B(02552)涨超5% 第二代GKA在美启动一期临床试验并完成首例受试者入组
华领医药-B盘中异动 下午盘大幅上涨5.59%报1.680港元
自选股智能写手 · 04-26
华领医药-B盘中异动 下午盘大幅上涨5.59%报1.680港元
华领医药-B(02552)上涨5.03%,报1.67元/股
金融界 · 04-26
华领医药-B(02552)上涨5.03%,报1.67元/股
华领医药(02552)创新药出海新突破!第二代GKA在美一期试验完成首例受试者入组
智通财经 · 04-26
华领医药(02552)创新药出海新突破!第二代GKA在美一期试验完成首例受试者入组
华领医药-B盘中异动 股价大涨5.40%
自选股智能写手 · 04-22
华领医药-B盘中异动 股价大涨5.40%
华领医药-B盘中异动 下午盘快速跳水5.23%
自选股智能写手 · 04-16
华领医药-B盘中异动 下午盘快速跳水5.23%
华领医药-B(02552)下跌7.83%,报1.53元/股
金融界 · 04-12
华领医药-B(02552)下跌7.83%,报1.53元/股
华领医药-B盘中异动 早盘大幅跳水5.36%报1.571港元
自选股智能写手 · 04-12
华领医药-B盘中异动 早盘大幅跳水5.36%报1.571港元
华领医药-B(02552)上涨5.56%,报1.71元/股
金融界 · 04-11
华领医药-B(02552)上涨5.56%,报1.71元/股
华领医药-B盘中异动 早盘大幅上涨5.49%
自选股智能写手 · 04-11
华领医药-B盘中异动 早盘大幅上涨5.49%
华领医药-B(02552)股价上升5.556%,现价港币$1.71
阿斯达克财经 · 04-11
华领医药-B(02552)股价上升5.556%,现价港币$1.71
华领医药-B现涨近9% 多格列艾汀成功获纳入国家医保药品目录
新浪港股 · 04-10
华领医药-B现涨近9% 多格列艾汀成功获纳入国家医保药品目录
东曜药业-B盘中异动 临近午盘股价大涨8.74%报1.730港元
自选股智能写手 · 04-10
东曜药业-B盘中异动 临近午盘股价大涨8.74%报1.730港元
港股异动 | 华领医药-B(02552)涨超12% 公司在手现金充沛 二代GKA美国临床顺利推进
智通财经网 · 04-10
港股异动 | 华领医药-B(02552)涨超12% 公司在手现金充沛 二代GKA美国临床顺利推进
华领医药-B(02552)上涨10.2%,报1.62元/股
金融界 · 04-10
华领医药-B(02552)上涨10.2%,报1.62元/股
华领医药-B盘中异动 大幅上涨6.12%
自选股智能写手 · 04-10
华领医药-B盘中异动 大幅上涨6.12%
华领医药-B(02552)股价上升6.122%,现价港币$1.56
阿斯达克财经 · 04-10
华领医药-B(02552)股价上升6.122%,现价港币$1.56
华领医药-B(02552)上涨8.46%,报1.41元/股
金融界 · 04-08
华领医药-B(02552)上涨8.46%,报1.41元/股
华领医药-B盘中异动 急速拉升5.46%报1.371港元
自选股智能写手 · 04-08
华领医药-B盘中异动 急速拉升5.46%报1.371港元
华领医药-B(02552)下跌5.84%,报1.29元/股
金融界 · 04-05
华领医药-B(02552)下跌5.84%,报1.29元/股
公司概况
公司名称:
华领医药-B
所属市场:
SEHK
上市日期:
--
主营业务:
华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力於开发用於治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。该公司主要在国内外市场开展业务。
发行价格:
--
{"stockData":{"symbol":"02552","market":"HK","secType":"STK","nameCN":"华领医药-B","latestPrice":1.59,"timestamp":1714723740030,"preClose":1.61,"halted":0,"volume":294000,"delay":0,"floatShares":1055588761,"shares":1055588761,"eps":-0.23471908,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.02,"latestTime":"05-03 16:09:00","open":1.6,"high":1.64,"low":1.55,"amount":467400,"amplitude":0.055901,"askPrice":1.61,"askSize":6000,"bidPrice":1.58,"bidSize":19500,"shortable":0,"etf":0,"ttmEps":-0.23471907566478142,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"listingDate":1536854400000,"adjPreClose":1.61,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.4820119375880144,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02552/wiki","defaultTab":"wiki","newsList":[{"id":"2430214794","title":"港股异动 | 华领医药-B(02552)涨超5% 第二代GKA在美启动一期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2430214794","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430214794?lang=zh_cn&edition=full","pubTime":"2024-04-26 14:18","pubTimestamp":1714112306,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,华领医药-B(02552)午后涨超5%,截至发稿,涨5.66%,报1.68港元,成交额164.71万港元。消息面上,华领医药今日宣布,其第二代葡萄糖激酶激活剂(第二代GKA)的一期临床试验已于美国正式启动,并完成第一例受试者入组。公司表示保留第二代GKA的全球专利权,一期临床试验顺利完成后,公司计划寻求合作伙伴,推进第二代GKA在全球市场的开发。西部证券此前指出,公司加速推进一期临床,同时积极寻求BD,完成下一代GKA药物的出海,进军全球降糖千亿美金市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111326.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430196982","title":"华领医药-B盘中异动 下午盘大幅上涨5.59%报1.680港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430196982","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430196982?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:39","pubTimestamp":1714109994,"startTime":"0","endTime":"0","summary":"2024年04月26日下午盘13时39分,华领医药-B股票出现波动,股价快速拉升5.59%。截至发稿,该股报1.680港元/股,成交量94.25万股,换手率0.09%,振幅5.66%。华领医药-B股票所在的生物技术行业中,整体涨幅为1.22%。其相关个股中,绿竹生物-B、泰格医药、君实生物涨幅较大,振幅较大的相关个股有泰格医药、永泰生物-B、君实生物,振幅分别为11.13%、10.68%、10.55%。华领医药-B公司简介:华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042613395487e841f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042613395487e841f6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430216256","title":"华领医药-B(02552)上涨5.03%,报1.67元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430216256","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430216256?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:30","pubTimestamp":1714109448,"startTime":"0","endTime":"0","summary":"4月26日,华领医药-B(02552)盘中上涨5.03%,截至13:30,报1.67元/股,成交146.24万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司,其核心产品华堂宁已获得中国国家药品监督管理局的上市批准,用于治疗成人2型糖尿病。临床试验显示,华堂宁能有效修复2型糖尿病患者的葡萄糖激酶,恢复血糖稳态,52周糖尿病缓解率达到65.2%。截至2023年年报,华领医药-B营业总收入7661.0万元、净利润-2.11亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26133040425641.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430215532","title":"华领医药(02552)创新药出海新突破!第二代GKA在美一期试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2430215532","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430215532?lang=zh_cn&edition=full","pubTime":"2024-04-26 12:56","pubTimestamp":1714107416,"startTime":"0","endTime":"0","summary":"据了解,华领医药于2023年12月末向FDA递交第二代GKA试验性新药研究申请并获受理,该申请于今年1月获批,一期临床试验已于近期正式启动,并已于美国当地时间4月25日完成首例受试者入组。公司期待看到第二代GKA一期临床试验能为药物疗效和安全性提供关键数据,为公司在海外市场的布局提供坚实基础。此外,华领医药保留第二代GKA的全球专利权,一期临床试验顺利完成后,公司计划寻求合作伙伴,推进第二代GKA在全球市场的开发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111305.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429911114","title":"华领医药-B盘中异动 股价大涨5.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429911114","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429911114?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:53","pubTimestamp":1713772413,"startTime":"0","endTime":"0","summary":"2024年04月22日临近收盘15时53分,华领医药-B股票出现异动,股价急速上涨5.40%。截至发稿,该股报1.581港元/股,成交量49万股,换手率0.05%,振幅6.67%。资金方面,该股资金流入53.1075万港元,流出14.205万港元。华领医药-B股票所在的生物技术行业中,整体涨幅为1.00%。华领医药-B公司简介:华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221553337a546e58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221553337a546e58&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427184218","title":"华领医药-B盘中异动 下午盘快速跳水5.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427184218","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427184218?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:16","pubTimestamp":1713248168,"startTime":"0","endTime":"0","summary":"2024年04月16日下午盘14时16分,华领医药-B股票出现异动,股价大幅下跌5.23%。截至发稿,该股报1.450港元/股,成交量62.15万股,换手率0.06%,振幅4.58%。华领医药-B股票所在的生物技术行业中,整体跌幅为1.02%。华领医药-B公司简介:华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力于开发用于治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041614160887e80dd4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041614160887e80dd4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426271472","title":"华领医药-B(02552)下跌7.83%,报1.53元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426271472","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426271472?lang=zh_cn&edition=full","pubTime":"2024-04-12 13:35","pubTimestamp":1712900101,"startTime":"0","endTime":"0","summary":"4月12日,华领医药-B(02552)盘中下跌7.83%,截至13:35,报1.53元/股,成交112.37万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司,其核心产品华堂宁已获得中国国家药品监督管理局的上市批准,用于治疗成人2型糖尿病。临床试验显示,华堂宁能有效修复2型糖尿病患者的葡萄糖激酶,恢复血糖稳态,52周糖尿病缓解率达到65.2%。截至2023年年报,华领医药-B营业总收入7661.0万元、净利润-2.11亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/12133540213252.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426242977","title":"华领医药-B盘中异动 早盘大幅跳水5.36%报1.571港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426242977","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426242977?lang=zh_cn&edition=full","pubTime":"2024-04-12 10:09","pubTimestamp":1712887752,"startTime":"0","endTime":"0","summary":"2024年04月12日早盘10时09分,华领医药-B股票出现异动,股价急速下跌5.36%。截至发稿,该股报1.571港元/股,成交量23.4万股,换手率0.02%,振幅5.42%。资金方面,该股资金流入8.832万港元,流出25.0665万港元。华领医药-B股票所在的生物技术行业中,整体跌幅为0.24%。华领医药-B公司简介:华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力于开发用于治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041210091287e7fc62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041210091287e7fc62&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426040396","title":"华领医药-B(02552)上涨5.56%,报1.71元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426040396","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426040396?lang=zh_cn&edition=full","pubTime":"2024-04-11 10:46","pubTimestamp":1712803601,"startTime":"0","endTime":"0","summary":"4月11日,华领医药-B(02552)盘中上涨5.56%,截至10:46,报1.71元/股,成交125.06万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司,其核心产品华堂宁已获得中国国家药品监督管理局的上市批准,用于治疗成人2型糖尿病。临床试验显示,华堂宁能有效修复2型糖尿病患者的葡萄糖激酶,恢复血糖稳态,52周糖尿病缓解率达到65.2%。截至2023年年报,华领医药-B营业总收入7661.0万元、净利润-2.11亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/11104640194820.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426087134","title":"华领医药-B盘中异动 早盘大幅上涨5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426087134","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426087134?lang=zh_cn&edition=full","pubTime":"2024-04-11 10:29","pubTimestamp":1712802596,"startTime":"0","endTime":"0","summary":"2024年04月11日早盘10时29分,华领医药-B股票出现异动,股价急速拉升5.49%。截至发稿,该股报1.710港元/股,成交量39.2万股,换手率0.04%,振幅6.79%。华领医药-B股票所在的生物技术行业中,整体跌幅为0.91%。其相关个股中,乐普生物-B、华领医药-B、宜明昂科-B涨幅较大,振幅较大的相关个股有乐普生物-B、宜明昂科-B、科伦博泰生物-B,振幅分别为10.33%、7.77%、7.36%。华领医药-B公司简介:华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411102957791fcdf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240411102957791fcdf8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426408505","title":"华领医药-B(02552)股价上升5.556%,现价港币$1.71","url":"https://stock-news.laohu8.com/highlight/detail?id=2426408505","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426408505?lang=zh_cn&edition=full","pubTime":"2024-04-11 10:29","pubTimestamp":1712802540,"startTime":"0","endTime":"0","summary":"[上升股]华领医药-B(02552) 股价在上午10:29比前收市价上升5.556%,现股价为港币$1.71。至目前为止,今日最高价为$1.71,而最低价为$1.6。总成交量为37.15万股,总成交金额为港币$61.652万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190212132919673_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240411733/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2426438362","title":"华领医药-B现涨近9% 多格列艾汀成功获纳入国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2426438362","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2426438362?lang=zh_cn&edition=full","pubTime":"2024-04-10 13:37","pubTimestamp":1712727478,"startTime":"0","endTime":"0","summary":"华领医药-B午后上涨8.84%,现报1.60港元,成交额334.933万港元。 华领医药此前发布2023年年报,报告期内,公司在全面推进多格列艾汀商业化道路上实现了里程碑式的成绩,多格列艾汀成功获纳入国家医保药品目录。公司已达到与多格列艾汀发展相关的若干里程碑,并获得不可退还里程碑付款人民币8亿元。此外,华领医药已在2023年底向FDA提交其第二代GKA的试验性新药申请并获得受理,以启动一期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-10/doc-inariqsx0190597.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-10/doc-inariqsx0190597.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426896204","title":"东曜药业-B盘中异动 临近午盘股价大涨8.74%报1.730港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426896204","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426896204?lang=zh_cn&edition=full","pubTime":"2024-04-10 11:47","pubTimestamp":1712720867,"startTime":"0","endTime":"0","summary":"2024年04月10日临近午盘11时47分,东曜药业-B股票出现波动,股价大幅拉升8.74%。截至发稿,该股报1.730港元/股,成交量800股,换手率0.00%,振幅0.00%。资金方面,该股资金流入1384港元,流出0港元。东曜药业-B股票所在的生物技术行业中,整体涨幅为0.36%。东曜药业-B公司简介:东曜药业股份有限公司是一家主要从事开发及商业化肿瘤药物及疗法的公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101147477a51c89e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101147477a51c89e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426710402","title":"港股异动 | 华领医药-B(02552)涨超12% 公司在手现金充沛 二代GKA美国临床顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2426710402","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2426710402?lang=zh_cn&edition=full","pubTime":"2024-04-10 10:26","pubTimestamp":1712715964,"startTime":"0","endTime":"0","summary":"华领医药-B(02552)涨超12%,截至发稿,涨12.24%,报1.65港元,成交额211.14万港元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20240410/20240410102720_20130.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240410/20240410102720_20130.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100413.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426109486","title":"华领医药-B(02552)上涨10.2%,报1.62元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426109486","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426109486?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:57","pubTimestamp":1712714253,"startTime":"0","endTime":"0","summary":"4月10日,华领医药-B(02552)盘中上涨10.2%,截至09:57,报1.62元/股,成交120.65万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司,其核心产品华堂宁已获得中国国家药品监督管理局的上市批准,用于治疗成人2型糖尿病。临床试验显示,华堂宁能有效修复2型糖尿病患者的葡萄糖激酶,恢复血糖稳态,52周糖尿病缓解率达到65.2%。截至2023年年报,华领医药-B营业总收入7661.0万元、净利润-2.11亿元。4月8日,太平洋维持买入评级,目标价上调至5.67港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/10095740176103.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426410910","title":"华领医药-B盘中异动 大幅上涨6.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426410910","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426410910?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:50","pubTimestamp":1712713848,"startTime":"0","endTime":"0","summary":"2024年04月10日早盘09时50分,华领医药-B股票出现波动,股价大幅拉升6.12%。截至发稿,该股报1.560港元/股,成交量29.65万股,换手率0.03%,振幅5.44%。华领医药-B股票所在的生物技术行业中,整体涨幅为0.06%。其相关个股中,华康生物医学、华领医药-B、帝王国际投资涨幅较大,振幅较大的相关个股有科伦博泰生物-B、科笛-B、药明生物,振幅分别为7.24%、5.71%、5.69%。华领医药-B公司简介:华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041009504887e7f048&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041009504887e7f048&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426109073","title":"华领医药-B(02552)股价上升6.122%,现价港币$1.56","url":"https://stock-news.laohu8.com/highlight/detail?id=2426109073","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426109073?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:50","pubTimestamp":1712713800,"startTime":"0","endTime":"0","summary":"[上升股]华领医药-B(02552) 股价在上午09:50比前收市价上升6.122%,现股价为港币$1.56。至目前为止,今日最高价为$1.56,而最低价为$1.48。总成交量为29.65万股,总成交金额为港币$44.292万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240410923/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2425314969","title":"华领医药-B(02552)上涨8.46%,报1.41元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425314969","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425314969?lang=zh_cn&edition=full","pubTime":"2024-04-08 14:07","pubTimestamp":1712556466,"startTime":"0","endTime":"0","summary":"4月8日,华领医药-B(02552)盘中上涨8.46%,截至14:07,报1.41元/股,成交100.49万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司,其核心产品华堂宁已获得中国国家药品监督管理局的上市批准,用于治疗成人2型糖尿病。临床试验显示,华堂宁能有效修复2型糖尿病患者的葡萄糖激酶,恢复血糖稳态,52周糖尿病缓解率达到65.2%。截至2023年年报,华领医药-B营业总收入7661.0万元、净利润-2.11亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/08140740144993.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425601624","title":"华领医药-B盘中异动 急速拉升5.46%报1.371港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425601624","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425601624?lang=zh_cn&edition=full","pubTime":"2024-04-08 09:34","pubTimestamp":1712540063,"startTime":"0","endTime":"0","summary":"2024年04月08日早盘09时34分,华领医药-B股票出现波动,股价大幅上涨5.46%。截至发稿,该股报1.371港元/股,成交量12万股,换手率0.01%,振幅5.38%。资金方面,该股资金流入12.798万港元,流出1.37万港元。华领医药-B股票所在的生物技术行业中,整体跌幅为0.04%。其相关个股中,泰格医药、康宁杰瑞制药-B、华领医药-B涨幅较大,振幅较大的相关个股有金斯瑞生物科技、来凯医药-B、科伦博泰生物-B,振幅分别为10.49%、7.83%、7.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080934237a513c08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080934237a513c08&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425587433","title":"华领医药-B(02552)下跌5.84%,报1.29元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425587433","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425587433?lang=zh_cn&edition=full","pubTime":"2024-04-05 14:56","pubTimestamp":1712300162,"startTime":"0","endTime":"0","summary":"4月5日,华领医药-B(02552)盘中下跌5.84%,截至14:56,报1.29元/股,成交136.65万元。华领医药是一家专注于未被满足的医疗需求的创新药物研发和商业化公司,其核心产品华堂宁已获得中国国家药品监督管理局的上市批准,用于治疗成人2型糖尿病。临床试验显示,华堂宁能有效修复2型糖尿病患者的葡萄糖激酶,恢复血糖稳态,52周糖尿病缓解率达到65.2%。截至2023年年报,华领医药-B营业总收入7661.0万元、净利润-2.11亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/05145640130545.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.huamedicine.com","stockEarnings":[{"period":"1week","weight":-0.0185},{"period":"1month","weight":0.1606},{"period":"3month","weight":-0.0422},{"period":"6month","weight":0.0258},{"period":"1year","weight":-0.4664},{"period":"ytd","weight":-0.1929}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华领医药是一家主要从事药物开发业务的中国公司。该公司目前致力於开发用於治疗2型糖尿病的口服新药Dorzagliatin或HMS5552。该公司主要在国内外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.009978},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.055195},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104259},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.047122},{"month":5,"riseRate":0.5,"avgChangeRate":0.074155},{"month":6,"riseRate":0.4,"avgChangeRate":0.059529},{"month":7,"riseRate":0.4,"avgChangeRate":0.046868},{"month":8,"riseRate":0.4,"avgChangeRate":-0.052673},{"month":9,"riseRate":0.6,"avgChangeRate":-0.033023},{"month":10,"riseRate":0,"avgChangeRate":-0.156577},{"month":11,"riseRate":0.666667,"avgChangeRate":0.132861},{"month":12,"riseRate":0.666667,"avgChangeRate":0.051948}],"exchange":"SEHK","name":"华领医药-B","nameEN":"HUA MEDICINE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华领医药-B,02552,华领医药-B股票,华领医药-B股票老虎,华领医药-B股票老虎国际,华领医药-B行情,华领医药-B股票行情,华领医药-B股价,华领医药-B股市,华领医药-B股票价格,华领医药-B股票交易,华领医药-B股票购买,华领医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华领医药-B(02552)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华领医药-B(02552)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}